Communications Biology (Feb 2021)
Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma
- Maeva Dufies,
- Annelies Verbiest,
- Lindsay S. Cooley,
- Papa Diogop Ndiaye,
- Xingkang He,
- Nicolas Nottet,
- Wilfried Souleyreau,
- Anais Hagege,
- Stephanie Torrino,
- Julien Parola,
- Sandy Giuliano,
- Delphine Borchiellini,
- Renaud Schiappa,
- Baharia Mograbi,
- Jessica Zucman-Rossi,
- Karim Bensalah,
- Alain Ravaud,
- Patrick Auberger,
- Andréas Bikfalvi,
- Emmanuel Chamorey,
- Nathalie Rioux-Leclercq,
- Nathalie M. Mazure,
- Benoit Beuselinck,
- Yihai Cao,
- Jean Christophe Bernhard,
- Damien Ambrosetti,
- Gilles Pagès
Affiliations
- Maeva Dufies
- Centre Scientifique de Monaco, Biomedical Department
- Annelies Verbiest
- Department of General Medical Oncology, University Hospitals Leuven
- Lindsay S. Cooley
- University of Bordeaux, INSERM U1029
- Papa Diogop Ndiaye
- LIA ROPSE, Laboratoire International Associé Université Côte d’Azur - Centre Scientifique de Monaco
- Xingkang He
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet
- Nicolas Nottet
- University Côte d’Azur, C3M, Inserm U1065
- Wilfried Souleyreau
- University of Bordeaux, INSERM U1029
- Anais Hagege
- LIA ROPSE, Laboratoire International Associé Université Côte d’Azur - Centre Scientifique de Monaco
- Stephanie Torrino
- University Côte d’Azur, Institut de Pharmacologie Cellulaire et Moléculaire, CNRS UMR7275
- Julien Parola
- LIA ROPSE, Laboratoire International Associé Université Côte d’Azur - Centre Scientifique de Monaco
- Sandy Giuliano
- LIA ROPSE, Laboratoire International Associé Université Côte d’Azur - Centre Scientifique de Monaco
- Delphine Borchiellini
- Centre Antoine Lacassagne
- Renaud Schiappa
- Centre Antoine Lacassagne
- Baharia Mograbi
- University Côte d’Azur, Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne
- Jessica Zucman-Rossi
- Inserm, UMR-1138, Génomique fonctionnelle des tumeurs solides, IUH
- Karim Bensalah
- Centre Hospitalier Universitaire (CHU) de Pontchaillou Rennes, service d’urologie
- Alain Ravaud
- Centre Hospitalier Universitaire (CHU) de Bordeaux, service d’oncologie médicale
- Patrick Auberger
- University Côte d’Azur, C3M, Inserm U1065
- Andréas Bikfalvi
- University of Bordeaux, INSERM U1029
- Emmanuel Chamorey
- Centre Antoine Lacassagne
- Nathalie Rioux-Leclercq
- Department of Pathology, University Hospital
- Nathalie M. Mazure
- University Côte d’Azur, C3M, Inserm U1065
- Benoit Beuselinck
- Department of General Medical Oncology, University Hospitals Leuven
- Yihai Cao
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet
- Jean Christophe Bernhard
- Centre Hospitalier Universitaire (CHU) de Bordeaux, service d’urologie
- Damien Ambrosetti
- University Côte d’Azur, Centre Hospitalier Universitaire (CHU) de Nice, Hôpital Pasteur, Central laboratory of Pathology
- Gilles Pagès
- Centre Scientifique de Monaco, Biomedical Department
- DOI
- https://doi.org/10.1038/s42003-021-01653-w
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 16
Abstract
Dufies et al. find high Plk1 expression levels in aggressive clear cell renal cell carcinoma and discover that Plk1 is transcriptionally upregulated in a manner dependent on HIF-2. They also find that high Plk1 expression is correlated to a poor prognosis and resistance to tyrosine kinase inhibitor against VEGF receptor, suggesting a critical role for hypoxia/HIF-2-induced Plk1 in disease progression.
